BioAtlantis Limited, a Tralee, Ireland-based biotechnology company, is leading a consortium of European SMEs and universities, which recently received €1.7m under the EU’s Research Framework programme (FP7).
The EU Research Project Thrive-Rite, which is the culmination of 8 years of collaborative research between BioAtlantis and the Agriculture & Food Science Centre at University College Dublin (UCD), has been granted a two year window to validate 4 natural alternatives to the use of in-feed growth promoting antibiotics, a practice banned by the EU in 2006.
If successful it is hoped that this will reduce the incidence of diseases such as Salmonella and E. Coli which are major causes of human food-borne illnesses and have a detrimental impact on the quality of farm produce and large-scale agricultural output across Europe.
A Bank of Ireland Kernel Capital Fund II portfolio company, BioAtlantis specializes in the research, development and manufacture of plant biostimulants and animal prebiotics using bioactive molecules derived from renewable natural resources, including seaweed. The company, which employs 15 staff, also operates processing facility in Kanturk, Co. Cork.
It received a €750,000 investment from Kernel Capital in 2010 (read here).